107 related articles for article (PubMed ID: 30825842)
1. Long-term survival of patients with prostate cancer in Martinique: Results of a population-based study.
Joachim C; Ulric-Gervaise S; Dramé M; Macni J; Escarmant P; Véronique-Baudin J; Vinh-Hung V
Cancer Epidemiol; 2019 Apr; 59():193-198. PubMed ID: 30825842
[TBL] [Abstract][Full Text] [Related]
2. Pattern of care of prostate cancer patients across the Martinique: results of a population-based study in the Caribbean.
Joachim C; Veronique-Baudin J; Ulric-Gervaise S; Macni J; Almont T; Pierre-Louis O; Godaert L; Drame M; Novella JL; Farid K; Vinh-Hung V; Escarmant P
BMC Cancer; 2018 Nov; 18(1):1130. PubMed ID: 30445934
[TBL] [Abstract][Full Text] [Related]
3. Cohort profile: the Martinique Cancer Registry and the quality of life prostate cancer cohort (QoL Prostate-MQ): challenges and prospects for reducing disparities in the Caribbean.
Joachim C; Veronique-Baudin J; Almont T; Ulric-Gervaise S; Macni J; Pierre-Louis O; Godaert L; Drame M; Novella JL; Farid K; Vinh-Hung V; Escarmant P
BMJ Open; 2018 Jul; 8(7):e021540. PubMed ID: 30049695
[TBL] [Abstract][Full Text] [Related]
4. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
Fossati N; Karnes RJ; Boorjian SA; Moschini M; Morlacco A; Bossi A; Seisen T; Cozzarini C; Fiorino C; Noris Chiorda B; Gandaglia G; Dell'Oglio P; Joniau S; Tosco L; Shariat S; Goldner G; Hinkelbein W; Bartkowiak D; Haustermans K; Tombal B; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2017 Jun; 71(6):886-893. PubMed ID: 27484843
[TBL] [Abstract][Full Text] [Related]
5. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.
Buzzoni C; Auvinen A; Roobol MJ; Carlsson S; Moss SM; Puliti D; de Koning HJ; Bangma CH; Denis LJ; Kwiatkowski M; Lujan M; Nelen V; Paez A; Randazzo M; Rebillard X; Tammela TL; Villers A; Hugosson J; Schröder FH; Zappa M
Eur Urol; 2015 Nov; 68(5):885-90. PubMed ID: 25791513
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.
Rider JR; Sandin F; Andrén O; Wiklund P; Hugosson J; Stattin P
Eur Urol; 2013 Jan; 63(1):88-96. PubMed ID: 22902040
[TBL] [Abstract][Full Text] [Related]
7. The U Shape of Prostate-specific Antigen and Prostate Cancer-specific Mortality in High-grade Metastatic Prostate Adenocarcinoma.
Wang J; Abudurexiti M; Shao N; Wei Y; Zhu Y; Ye DW
Eur Urol Focus; 2020 Jan; 6(1):53-62. PubMed ID: 30217630
[TBL] [Abstract][Full Text] [Related]
8. Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigen.
Falchook AD; Martin NE; Basak R; Smith AB; Milowsky MI; Chen RC
Urol Oncol; 2016 Mar; 34(3):119.e19-26. PubMed ID: 26526383
[TBL] [Abstract][Full Text] [Related]
9. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.
Abdollah F; Sood A; Sammon JD; Hsu L; Beyer B; Moschini M; Gandaglia G; Rogers CG; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
Eur Urol; 2015 Sep; 68(3):497-505. PubMed ID: 26119559
[TBL] [Abstract][Full Text] [Related]
10. Population-based study of grade progression in patients who harboured Gleason 3 + 3.
Sampurno F; Earnest A; Millar J; Frydenberg M; Murphy D; Delprado W; Evans S
World J Urol; 2017 Nov; 35(11):1689-1699. PubMed ID: 28500489
[TBL] [Abstract][Full Text] [Related]
11. Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer.
Stish BJ; Pisansky TM; Harmsen WS; Davis BJ; Tzou KS; Choo R; Buskirk SJ
J Clin Oncol; 2016 Nov; 34(32):3864-3871. PubMed ID: 27480153
[TBL] [Abstract][Full Text] [Related]
12. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M
Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
[TBL] [Abstract][Full Text] [Related]
13. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.
Godtman RA; Holmberg E; Khatami A; Stranne J; Hugosson J
Eur Urol; 2013 Jan; 63(1):101-7. PubMed ID: 22980443
[TBL] [Abstract][Full Text] [Related]
14. The relationship between the extent of extraprostatic extension and survival following radical prostatectomy.
Jeong BC; Chalfin HJ; Lee SB; Feng Z; Epstein JI; Trock BJ; Partin AW; Humphreys E; Walsh PC; Han M
Eur Urol; 2015 Feb; 67(2):342-6. PubMed ID: 24968968
[TBL] [Abstract][Full Text] [Related]
15. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.
Xie W; Regan MM; Buyse M; Halabi S; Kantoff PW; Sartor O; Soule H; Berry D; Clarke N; Collette L; D'Amico A; Lourenco RA; Dignam J; Eisenberger M; James N; Fizazi K; Gillessen S; Loriot Y; Mottet N; Parulekar W; Sandler H; Spratt DE; Sydes MR; Tombal B; Williams S; Sweeney CJ;
J Clin Oncol; 2020 Sep; 38(26):3032-3041. PubMed ID: 32552276
[TBL] [Abstract][Full Text] [Related]
16. Reduced cancer-specific survival of low prostate-specific antigen in high-grade prostate cancer: A population-based retrospective cohort study.
Song P; Yang B; Peng Z; Zhou J; Ren Z; Fang K; Yang L; Wang L; Dong Q
Int J Surg; 2020 Apr; 76():64-68. PubMed ID: 32109649
[TBL] [Abstract][Full Text] [Related]
17. Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy.
Bryant AK; D'Amico AV; Nguyen PL; Einck JP; Kane CJ; McKay RR; Simpson DR; Mundt AJ; Murphy JD; Rose BS
Cancer; 2018 Jul; 124(14):2939-2947. PubMed ID: 29727915
[TBL] [Abstract][Full Text] [Related]
18. The number of risk factors is the strongest predictor of prostate cancer mortality: multi-institutional outcomes of an extreme-risk prostate cancer cohort.
Gomez-Iturriaga A; Cabeza Á; Pastor J; Jove J; Casaña M; Caamaño AG; Mengual J; Henríquez I; Muñoz J; Hervás A; Segundo CG
Clin Transl Oncol; 2016 Oct; 18(10):1026-33. PubMed ID: 26781470
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
[TBL] [Abstract][Full Text] [Related]
20. Does screening for prostate cancer improve cancer-specific mortality in Asian men? Real-world data in Yokosuka City 15 years after introducing PSA-based population screening.
Tabei T; Taguri M; Sakai N; Koh H; Yosida M; Fujikawa A; Nirei T; Tsutsumi S; Ito H; Furuhata S; Kawahara T; Miyoshi Y; Noguchi S; Uemura H; Kobayashi K
Prostate; 2020 Aug; 80(11):824-830. PubMed ID: 32433780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
